Waiting for green cards, Indian visa-holders see hope in Trump review

April 22, 2017

San Francisco, Apr 22: When Gokul Gunasekaran was offered a full scholarship for a graduate program in electrical engineering at Stanford University, he saw it as the chance of a lifetime.

trum66He had grown up in Chennai, India, and had a solid job offer with a large oil company after getting his undergraduate degree. He came to America instead, got the Stanford degree and now works as an engineer at a data science startup in Silicon Valley.

But for the past five years, he has been waiting for a green card that would give him full legal rights as a permanent resident. In the meantime, he is in a holding pattern on an H1-B visa, which permits him to live and work in the United States but does not allow him easily to switch jobs or start his own company.

"It was a no-brainer when I came to this country, but now I'm kind of regretting taking that scholarship," said Gunasekaran, 29, who is also vice president with a non-profit group called Immigration Voice that represents immigrants waiting for green cards.

Immigration Voice estimates there are some 1.5 million H1-B visa holders in the country waiting for green cards, many of whom are from India and have been waiting for more than a decade.

Many of these immigrants welcomed President Donald Trump's executive order this week to the federal departments overseeing the program to review it, a move that may lead to H1-B visas being awarded to the highest-paying, highest-skilled jobs rather than through a random lottery.

Their hope is that merit-based H1-Bs might then lead to merit-based green cards.

"I think less random is great," said Guru Hariharan, the CEO and founder of Boomerang Commerce, an e-commerce startup. Hariharan, who was previously an executive at Amazon.com Inc and eBay Inc, spent 10 years waiting for his green card and started his own company as soon as he got it.

Green cards can be a path to naturalization and Hariharan expects to become a U.S. citizen soon.

H1-B visas are aimed at foreign nationals in occupations that generally require specialized knowledge, such as science, engineering or computer programming. The U.S. government uses a lottery to award 65,000 such visas yearly and randomly distributes another 20,000 to graduate student workers.

'Indentured servants'

The H1-B and the green card system are technically separate, but many immigrants from India see them as intimately connected.

The number of green cards that can go to people born in each country is capped at a few percent of the total, without regard to how large or small the country's population is. There is a big backlog of Indian-born people in the line, given the size of India's population - 1.3 billion - and the number of its natives in the United States waiting for green cards.

That leaves many of those immigrants stuck on H1-B visas while they wait, which they say makes them almost like "indentured servants," said Gaurav Mehta, an H1-B holder who works in the financial industry.

Mehta has a U.S.-born son, but he could be forced to take his family back to India at any time if he loses his job and cannot find another quickly. "He's never been to my country," Mehta said of his son. "But we'll have no choice if we have to go. Nobody likes to live in constant fear."

The H1-B visa is tied to a specific employer, who must apply for the visa and sponsor the employee for a specific job laid out in the visa application. To switch employers, the visa holder must secure their paperwork from their current employer and find another employer willing to take over their visa.

Some H1-B holders suspect that employers purposely seek out Indian immigrants because they know they will end up waiting for green cards and will be afraid to leave their employers.

But changing the green card system away from country caps to a merit-based system would require an act of Congress. Some executives also worry that allocating H1-Bs and green cards based on salary - while it would be done to counter the argument that immigrants undercut American workers - would hurt startups that cannot afford high wages.

In the meantime, H1-B holders like Nitin Pachisia, founding partner of a venture capital firm called Unshackled Ventures, are taking more practical measures. His firm specializes in taking care of the legal paperwork so that H1-B holders can start their own companies, a process that is possible but tricky.

Pachisia is hopeful that changes to the H1-B visa program could revive interest in making the entire system, from H1-B visas to green cards and eventual citizenship, more merit-based and focused on immigrants who are likely to start companies and create jobs.

"If the purpose of our high-skilled immigration program is to bring in the most talented people, let's use that as a lens. From that perspective, it's a good thing we can focus on the most talented, and I'd say most entrepreneurial, people," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 7,2020

Russia boasts that it's about to become the first country to approve a Covid-19 vaccine, with mass vaccinations planned as early as October using shots that are yet to complete clinical trials -- and scientists worldwide are sounding the alarm that the headlong rush could backfire.

Moscow sees a Sputnik-like propaganda victory, recalling the Soviet Union's launch of the world's first satellite in 1957.

But the experimental Covid-19 shots began first-in-human testing on a few dozen people less than two months ago, and there's no published scientific evidence yet backing Russia's late entry to the global vaccine race, much less explaining why it should be considered a front-runner.

“I'm worried that Russia is cutting corners so that the vaccine that will come out may be not just ineffective, but also unsafe,” said Lawrence Gostin, a global public health law expert at Georgetown University. “It doesn't work that way... Trials come first. That's really important.”

According to Kirill Dmitriev, head of Russia's Direct Investment Fund that bankrolled the effort, a vaccine developed by the Gamaleya research institute in Moscow may be approved in days, before scientists complete what's called a Phase 3 study.

That final-stage study, usually involving tens of thousands of people, is the only way to prove if an experimental vaccine is safe and really works.

Health Minister Mikhail Murashko said members of “risk groups,” such as medical workers, may be offered the vaccine this month.

He didn't clarify whether they would be part of the Phase 3 study that is said to be completed after the vaccine receives “conditional approval.”

Deputy Prime Minister Tatyana Golikova promised to start “industrial production” in September, and Murashko said mass vaccination may begin as early as October.

Dr Anthony Fauci, the top US infectious disease specialist, questioned the fast-track approach last week.

“I do hope that the Chinese and the Russians are actually testing a vaccine before they are administering the vaccine to anyone, because claims of having a vaccine ready to distribute before you do testing I think is problematic at best," he said.

Questions about this vaccine candidate come after the US, Britain and Canada last month accused Russia of using hackers to steal vaccine research from Western labs.

Delivering a vaccine first is a matter of national prestige for the Kremlin as it tries to assert the image of Russia as a global power capable of competing with the US and China.

The notion of being “the first in the world” dominated state news coverage of the effort, with government officials praising reports of the first-step testing.

In April, President Vladimir Putin ordered state officials to shorten the time of clinical trials for a variety of drugs, including potential coronavirus vaccines.

According to Russia's Association of Clinical Trials Organizations, the order set “an unattainable bar” for scientists who, as a result, "joined in on the mad race, hoping to please those at power.”

The association first raised concern in late May, when professor Alexander Gintsburg, head of the Gamaleya institute, said he and other researchers tried the vaccine on themselves.

The move was a “crude violation of the very foundations of clinical research, Russian law and universally accepted international regulations" the group said in an open letter to the government, urging scientists and health officials to adhere to clinical research standards.

But a month later, the Health Ministry authorized clinical trials of the Gamaleya product, with what appeared to be another ethical issue.

Human studies started June 17 among 76 volunteers. Half were injected with a vaccine in liquid form and the other half with a vaccine that came as soluble powder.

Some in the first half were recruited from the military, which raised concerns that servicemen may have been pressured to participate.

Some experts said their desire to perform well would affect the findings. “It's no coincidence media reports we see about the trials among the military said no one had any side effects, while the (other group) reported some," said Vasily Vlassov, a public health expert with Moscow's Higher School of Economics.

As the trials were declared completed and looming regulatory approval was announced last week, questions arose about the vaccine's safety and effectiveness.

Government assurances the drug produced the desired immune response and caused no significant side effects were hardly convincing without published scientific data describing the findings.

The World Health Organization said all vaccine candidates should go through full stages of testing before being rolled out.

“There are established practices and there are guidelines out,” WHO spokesman Christian Lindmeier said Tuesday.

“Between finding or having a clue of maybe having a vaccine that works, and having gone through all the stages, is a big difference.”

Offering an unsafe compound to medical workers on the front lines of the outbreak could make things worse, Georgetown's Gostin said, adding: “What if the vaccine started killing them or making them very ill?”

Vaccines that are not properly tested can cause harm in many ways — from a negative impact on health to creating a false sense of security or undermining trust in vaccinations, said Thomas Bollyky, director of the global health program at the Council on Foreign Relations. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 22,2020

London, Apr 22: The UK government on Tuesday announced a 20 million pounds funding for a University of Oxford project working on developing a vaccine against the novel coronavirus, which is now ready for acceleration as it begins human trials from Thursday.

UK Health Secretary Matt Hancock told the daily Downing Street briefing that the Department for Health was “throwing everything” at trying to find a vaccine because it is a critical aspect of the COVID-19 pandemic fight and lifting the strict lockdown measures in place to curb its spread.

Another 22.5 million pounds is being made available to Imperial College London to support its phase-two clinical trials for them to begin the work on a very large phase three trial.

"Normally it would take years to get to this point," said Hancock.

"The UK is at the forefront of the global effort – we've put in more money than any other into the global search for a vaccine. Nothing about this is inevitable. Vaccine production is a matter of trial and error. But the UK will throw everything it has at trying to find one,” he said.

The announcement came as Britain had another major daily leap in the hospital death toll from coronavirus, up by 823 to hit 17,337 on Tuesday.

But the Cabinet minister said the government's plan to control the rapid spread of the virus and prevent the state-funded National Health Service (NHS) from being overwhelmed is working as the number of hospitalisations with COVID-19 was showing a downward trajectory.

In reference to a major issue in the last few weeks of a critical shortage of personal protective equipment (PPE) for doctors and nurses on the frontlines of COVID-19 treatment, the minister said the supply problems are being addressed by actively engaging with thousands of companies, including 159 UK manufacturers.

“We are determined to get people the PPE they need. This is a 24/7 operation, one of the biggest cross-government operation I have ever seen," said Hancock.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.